Four British Medical Journal
(BMJ) articles have challenged
Boehringer Ingelheim’s decision
to withhold significant data from
regulators around the safety of
Pradaxa (dabigatran) while it was
under review, reports Medscape.
The company, the reports allege,
kept private the conclusion of at
least some of its researchers that
monitoring-guided dabigatran
dosing “has the potential to provide
patients an even better efficacy
and safety profile than fixed-dose
dabigatran and also a better safety
and efficacy profile than a matched
warfarin group.”
CLICK HERE to read the
Medscape review.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jul 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.